11-13 November 2025
Congress Center BaselBasel, Switzerland David Butler, PhDChief Technology Officer at Hongene Biotech CorporationSpeaker
Profile
| David Butler, PhD, is the Chief Technology Officer at Hongene Biotech Corporation. Prior to joining Hongene, he led organizations driving drug discovery and development of oligonucleotide therapeutics, most recently as Head of Chemistry at Korro Bio, Head of Therapeutics Development at Alltrna, and Head of Medicinal Chemistry at Wave Life Sciences. He began his career in oligonucleotides at Alnylam Pharmaceuticals developing early LNP technologies for siRNA delivery that were the progenitors of those used for mRNA related products today. He is passionate about working with individuals and companies to help them succeed, and advancing manufacturing technologies to make RNA medicines more accessible and affordable for patients, regardless of their income or location. |
Agenda Sessions
Chemoenzymatic Ligation: Advancing Next-Generation Manufacturing Technologies for siRNA and sgRNA
, 12:15View Session